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COMMENTARY

Lost in Translation:
A Disconnect Between the Science and Medicare Coverage
Criteria for Continuous Subcutaneous Insulin Infusion
Grazia Aleppo, MD, FACE, FACP,1 Christopher G. Parkin, MS,2,i Anders L. Carlson, MD,3–5
Rodolfo J. Galindo, MD, FACE,6–8,ii Davida F. Kruger, MSN, APRN-BC, BC-ADM,9
Carol J. Levy, MD, CDE,10,11 Guillermo E. Umpierrez, MD, CDE, FACE, MACP,12,13
Gregory P. Forlenza, MD,14,iii and Janet B. McGill, MD, MA, FACE, FACP15,iv
Abstract

Numerous studies have demonstrated the clinical value and safety of insulin pump therapy in type 1 diabetes
and type 2 diabetes populations. However, the eligibility criteria for insulin pump coverage required by the
Centers for Medicare & Medicaid Services (CMS) discount conclusive evidence that supports insulin pump use
in diabetes populations that are currently deemed ineligible. This article discusses the limitations and inconsistencies of the insulin pump eligibility criteria relative to current scientific evidence and proposes workable solutions to address this issue and improve the safety and care of all individuals with diabetes.
Keywords: CSII, AID, HCL, LGS, PLGS, Centers for Medicare & Medicaid Services, Insurance coverage,
Type 1 diabetes, Type 2 diabetes.
commercial payers, worldwide. In the United States, the total
estimated cost of diagnosed diabetes exceeded $327 billion
in 2017,1 with the cost of undiagnosed diabetes estimated at
almost $32 billion.2 Approximately $180 billion (55%) of
these costs for diagnosed diabetes are related to treating the

Introduction

A

s the prevalence of diabetes continues to increase,
managing the costs associated with treating the disease
and its complications is problematic for government and
1

Division of Endocrinology, Metabolism and Molecular Medicine, Feinberg School of Medicine, Northwestern University, Chicago,
Illinois, USA.
2
Clinical Research, CGParkin Communications, Inc., Henderson, Nevada, USA.
3
International Diabetes Center, Endocrinologist, Regions Hospital & HealthPartners Clinics, Minneapolis, Minnesota, USA.
4
Diabetes Education Programs, HealthPartners and Stillwater Medical Group, Minneapolis, Minnesota, USA.
5
University of Minnesota Medical School, Minneapolis, Minnesota, USA.
6
Emory University School of Medicine, Atlanta, Georgia, USA.
7
Center for Diabetes Metabolism Research Emory University Hospital Midtown, Atlanta, Georgia, USA.
8
Hospital Diabetes Taskforce, Emory Healthcare System, Atlanta, Georgia, USA.
9
Division of Endocrinology, Diabetes, Bone & Mineral, Henry Ford Health System, Detroit, Michigan, USA.
10
Division of Endocrinology, Diabetes, and Metabolism, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
11
Mount Sinai Diabetes Center and T1D Clinical Research, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
12
Division of Endocrinology, Metabolism Emory University School of Medicine, Atlanta, Georgia, USA.
13
Diabetes and Endocrinology, Grady Memorial Hospital, Atlanta, Georgia, USA.
14
Barbara Davis Center, Division of Pediatric Endocrinology, Department of Pediatrics, University of Colorado Denver, Denver,
Colorado, USA.
15
Division of Endocrinology, Metabolism and Lipid Research, Washington University in St. Louis, School of Medicine, St. Louis,
Missouri, USA.
i
ORCID ID (https://orcid.org/0000-0001-6838-5355).
ii
ORCID ID (https://orcid.org/0000-0002-9295-3225).
iii
ORCID ID (https://orcid.org/0000-0003-3607-9788).
iv
ORCID ID (https://orcid.org/0000-0002-6228-6521).
ª Grazia Aleppo, et al., 2021; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the
Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly credited.

1

2

complications of diabetes that arise from suboptimal glycemic control. These costs include inpatient hospitalizations
($69.6 billion), emergency department/ambulance services
($8.3 billion), hospital outpatient care ($12.0), and lost productivity ($90.0 billion),1 whereas the cost of medical equipment, including glucose monitoring devices and insulin pumps,
comprise only $1.3 billion (0.4%).
The increasing prevalence of diabetes is worrisome in the
Medicare population. Approximately 26.8% of U.S. adults at
age ‡65 years have diabetes.3 Within the Medicare population, the prevalence of diabetes was 31.6% according to the
latest estimates (2015).4 Within this population, the average
per capita cost of diabetes is two times greater than individuals at age <65 years, $13,239 versus $6675, respectively.1
Treatment of older insulin-treated diabetes patients is particularly challenging because of their comorbidities, including
cardiovascular and kidney disease, cognitive decline, and orthopedic problems causing impaired mobility. Older patients
with diabetes of long duration are more likely to need insulin
therapy and are at increased risk for hyperglycemia, severe
hypoglycemia, and glucose variability and have a higher
prevalence of impaired hypoglycemia awareness.5–10 The increased risk of severe hypoglycemia among patients ‡65 years
occurs with both intensive insulin regimens and with less intensive insulin regimens or oral antidiabetic medications.11–13
As reported by Lipska et al. in a retrospective analysis
of Medicare beneficiaries, data from 1999 to 2011 showed
an 11.7% increase in inpatient admission rates for severe
hypoglycemia (from 94 to 105 admissions per 100,000
person-years).14 In 2011 the average cost per hypoglycemia hospitalization was $10,139,15 which equates to
$13,265 when inflated to US$ 2021.16
The logical approach to improving outcomes and reducing these costs would be to encourage greater use of tools
that have been proven effective in addressing dysglycemia,
including elevated HbA1c levels and excessive glycemic
variability leading to hypoglycemia. All are significant risk
factors for developing acute17–19 and chronic19–23 complications of diabetes. Among these tools is insulin pump therapy.
Numerous studies have demonstrated the efficacy of insulin pump use, with and without continuous glucose monitoring (CGM) in individuals with type 1 diabetes (T1D).24–32
However, a growing body of evidence shows similar benefits
in individuals with type 2 diabetes (T2D) who are treated
with multiple daily insulin injections (MDI).33–44
Although the majority of T2D studies have shown only
short-term benefits of insulin pump therapy, a 5-year followup study of insulin pump use in T2D adults showed persistent
glycemic benefits in this population.33 Another example is
the prospective, crossover trial by Chlup et al., which showed
that T2D adults previously treated with MDI therapy who
initiated insulin pump therapy experienced significant HbA1c
reductions (-0.9%), whereas those who remained on MDI
therapy showed no improvement at 6 months.43 At 12 months,
earlier MDI users who crossed over to insulin pump showed
significant HbA1c reductions (-0.5%), whereas those who
continued insulin pump therapy achieved an additional
HbA1c reduction (-0.7%).
The safety and efficacy of insulin pump therapy in patients
with T2D were also demonstrated in the Opt2mise program, in
which participants who failed to achieve adequate glycemic
control on MDI therapy achieved significant, sustained im-
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provements in glycemic outcomes when switched to insulin
pump therapy.35 In the recent VIVID study that assessed glycemic variability and time in optimal glucose range in a subset
of T2D adults who required high doses of insulin, Blevins et al.
reported that participants using continuous subcutaneous insulin infusion (CSII) experienced significant reductions in
glycemic variability compared with those treated with MDI.45
The efficacy of insulin pump therapy in reducing hypoglycemia risk in older patients was demonstrated in a study by
Yeoh et al. that assessed changes in HbA1c and hypoglycemia
in 34 patients, >65 years of age.46 Significant reductions in
HbA1c were observed at 1 year and sustained for up to 9 years.
Of importance, in the 28 patients with documented status of
hypoglycemia awareness, the proportion of patients reporting
impaired awareness decreased from 50% to 40.6% during the
first year of insulin pump use. Among the 22 patients who
initiated insulin pump therapy because of disabling hypoglycemia, the proportion of patients reporting ‡1 episode at
baseline decreased from 58.3% to 16.7%.
We also have a new generation of insulin-delivery technologies that can detect and or predict dangerous glycemic
events and then automatically suspend or increase insulin
infusion. These new devices both improve overall glycemic
control and reduce hypoglycemia, which numerous studies
have shown to be common occurrences and a significant risk
factor for hospitalizations and mortality among older adults
with diabetes.5–10 Moreover, these systems have been shown
to increase the time spent in each user’s target glucose range,
reducing time spent in hyperglycemic and in hypoglycemic
ranges, which are risks not detected through HbA1c testing.
Frequent and/or excessive glycemic variability47 poses significant risks for acute and chronic diabetes complications.48
As demonstrated in the 2018 Tandem Basal-IQ study involving 103 T1D participants (age 6–72 years), use of the
Tandem Diabetes Care Basal-IQ predictive low-glucose
suspend (PLGS) system (Tandem Diabetes Care, Inc., San
Diego, CA) integrated with a Dexcom G5 sensor (Dexcom,
Inc., San Diego, CA) and a PLGS algorithm resulted in
significantly reduced hypoglycemia without rebound hyperglycemia, demonstrating that the system can improve glycemic control in youth and adults.49 More recently, real-world
data from 9451 Tandem Control-IQ users showed increased
time in glucose range with reduced time above range over 12
months.50 Most of these individuals were using the Basal-IQ
system before the Control-IQ.
The MiniMed 780G US Pivotal Trial was a single-arm
study that compared the sensor-augmented Medtronic
MiniMed 780G Advanced Hybrid Closed Loop (AHCL)
(Medtronic, Inc., Northridge, CA) with sensor-augmented
pump therapy or MiniMed 670G in a cohort of 157 T1D
adolescents and adults.51 At 3 months, use of the AHCL was
associated with reduced hypoglycemia and improved HbA1c.
Similar glycemic benefits were reported with use of the
OmniPod 5 (Insulet Corp., San Diego, CA)52 and the Loop
open source hybrid closed loop system (LoopDocs).53 Note
that insulin-requiring patients with T2D on MDI therapy
currently qualify for the use of CGM, but most Medicare
beneficiaries do not qualify for insulin pump use.
It is, therefore, unfortunate that many Medicare beneficiaries with insulin-treated diabetes who would benefit from
insulin pump use are denied access to this technology because of onerous, medically unfounded eligibility criteria.
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This article discusses the limitations and inconsistencies of
the Medicare coverage requirements relative to current scientific evidence and proposes workable solutions to address
this issue and improve the safety and care of all individuals
with diabetes.
Current Eligibility Criteria Are Based on Outdated
or No Scientific Evidence

When making its determination for coverage of insulin
pump therapy for Medicare beneficiaries54 (Table 1), the
Centers for Medicare & Medicaid Services (CMS) performed
a rigorous review of the literature. As detailed in their document, Decision Memo for Insulin Pump: C-Peptide Levels
as a Criterion for Use (CAG-00092R),55 the agency considered the available relevant studies and professional society
consensus statements to determine whether the evidence
was of sufficient quality to support insulin pump coverage.
However, because the determination was made in 2004, the
most recent and relevant studies were, by default, excluded
from their assessment.24–43,56–58
As a result, the clinical efficacy of today’s advanced
insulin-delivery technologies integrated with continuous
glucose sensor technology were not considered. Moreover,
these outdated criteria do not reflect important current evidence that is unsupportive or clearly refutes many of the
original criteria, such as documentation of insulinopenia,
frequent blood glucose monitoring (BGM), and quarterly inperson health care provider evaluation. These onerous and
unnecessary requirements severely impede beneficiary access to the proven benefits of insulin pump therapy. The
following is a point-by-point assessment of the validity of the
current eligibility criteria.
Proof of insulinopenia is irrelevant to success
with insulin pump therapy

According to the Medicare Decision Memo for Insulin
Pump use:55
CMS has determined that the evidence is adequate to conclude that continuous subcutaneous insulin infusion (CSII) is
reasonable and necessary for treatment of diabetic patients:
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(1) who either meet the updated fasting C-peptide testing requirement or are beta cell autoantibody positive; and (2) who
satisfy the remaining criteria for insulin pump therapy detailed
in the Medicare National Coverage Determinations Manual.

This requirement was drafted almost two decades ago and
our understanding of the relevance of C-peptide assessment
has evolved to the point where this requirement is no longer
consistent with the science. Moreover, these tests are costly,
add no value to clinical decision-making, and impose additional burdens on patients and their health care providers.
Limitations of C-peptide and islet antibody assessments.

Although a fasting C-peptide test is a useful indicator of beta
cell function and has been shown to correlate with diabetes
type, duration of T2D, and age of diagnosis,59 the accuracy
of this measurement can be impacted by a number of factors.
The presence of a large numbers of anti-insulin antibodies
that bind both proinsulin and C-peptide can yield a falsely
high C-peptide reading.59 Moreover, studies published after
the Medicare requirement have shown the persistence of
C-peptide levels in individuals with T1D.60–63
The limitations of C-peptide testing in T2D are even more
profound. As demonstrated in a recent study by Khan et al. a
higher C-peptide level is a strong marker for insulin resistance64 and is consistently associated with cardiovascular
and all-cause mortality in people without diabetes.65–67
Therefore, one would expect to see higher C-peptide levels in
individuals with T2D, given the high prevalence of insulin
resistance and obesity in these individuals.68 Conversely, as
recently reported by Christensen et al., low C-peptide levels
are associated with increased glycemic variability and hypoglycemia risk.69
To our knowledge, no study has shown a correlation of
islet autoantibody levels and glycemic control. In fact, a recent study by Gumus et al. showed that islet antibody status
was not associated with differences in insulin, C-peptide
levels, or HbA1c levels.70 Moreover, use of islet antibody
testing limits insulin pump use to patients with autoimmune
diabetes, which excludes most insulin-requiring patients with
T2D, and certainly excludes those with insulin deficiency
from other conditions such as pancreatic disease or resection

Table 1. Current Medicare Eligibility Criteria for Insulin Pump Coverage54
Insulin pumps are covered as medically reasonable and necessary in the home setting for individuals with diabetes who
(1) either meet the specified fasting C-peptide testing requirement, or, are beta cell autoantibody positive; and, (2) satisfy
the remaining criteria for insulin pump therapy as described hereunder:54
 Has completed a comprehensive diabetes education program
 Documentation of treatment with multiple daily injections of insulin (‡3 injections daily) for at least 6 months before
initiation of the insulin pump
 Documentation of blood glucose monitoring frequency (‡4 tests daily) during the 2 months before initiation of the insulin
pump. This also applies to beneficiaries who have been on insulin pump therapy before Medicare enrollment
 Meets one or more of the following requirements:
B >7.0% HbA1c
B Documented history of recurring hypoglycemia
B Documentation of wide fluctuations in blood glucose before mealtime
B Documentation of dawn phenomenon with fasting blood glucose frequently >200 mg/dL
B Documentation of history of severe glycemic excursions
 Continued coverage requirements:
B The beneficiary is seen and evaluated by the treating physician at least every 3 months
B The pump must be ordered by and follow-up care of the patient must be managed by a physician who manages
multiple patients using insulin pumps and who works closely with a team including nurses, diabetes educators,
and dietitians who are knowledgeable in the use of insulin pumps
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and insulin-requiring patients with other types of diabetes,
including gestational diabetes or T2D in pregnancy, where
tight glucose control is mandatory.
No relationship between C-peptide/islet antibody measures and outcomes with insulin pump therapy. Although

testing for C-peptide and islet or beta cell antibody levels may
be valuable for diagnostic purposes, these measurements are
irrelevant to whether an individual would benefit from insulin
pump therapy. Current clinical practice guidelines recommend insulin use based on glycemic status and not on insulinproducing capacity or antibody status.71 Therefore, it does a
disservice to require patients to wait until they reach insulinopenia before offering therapy that could improve glycemia
and reduce complications. As demonstrated in numerous
studies, the glycemic benefits of insulin pump therapy are not
dependent on detection of C-peptide concentrations or detection of autoantibodies.34–36,56,72–74
In a retrospective study that assessed a propensity scorematched cohort of insulin pump and MDI users, Gill et al.
investigated the differences in health care resource utilization
and costs between individuals with T1D and T2D treated with
insulin pump or MDI therapy who met or did not meet the
Medicare C-peptide/beta cell antibody eligibility criteria.56
For these comparisons, investigators structured the study as
three analyses. Results from the first analysis showed significantly slower growth in hospital admissions and average
annual medical costs among insulin pump users who did not
meet the C-peptide/beta cell antibody test criteria compared
with those who did, although changes in total medical costs
were similar. Although results from the second analysis
showed slower growth in inpatient costs at 1 year, similar
changes in total medical costs were observed.
In both analyses, insulin pump adopters who did not meet
Medicare test criteria showed numerically slower growth in
inpatient, outpatient, emergency department costs, and hospital admissions compared with analogous MDI groups. In
the third analysis, slower growth in hospital admissions was
observed in the insulin pump group compared with MDI
therapy, and per-patient annual savings ranged from $201 for
emergency department costs to $5133 for total medical costs.
In the OpT2mise trial, a randomized, controlled, multicenter study of 331 T2D adults with suboptimal glycemic control
(>9.0% HbA1c), participants were randomized to insulin
pump or MDI therapy and were followed for 6 months.35,72
Among the study participants, 18% were positive for antiglutamic acid decarboxylase antibody (anti-GAD Ab) levels
and 24% had undetectable C-peptide levels. Of importance,
baseline HbA1c values were not correlated with either antiGAD Ab or C-peptide concentrations. At 6 months, the mean
HbA1c in the insulin pump group had decreased 1.1% versus
0.4% in the MDI group, with a between-group difference of
-0.7% (P < 0.0001).
However, there was no association between HbA1c reductions and C-peptide concentration in both the insulin pump and
MDI groups. Regardless of the insulin delivery method used,
the mean HbA1c value decreased equally in each anti-GAD Ab
category and in each C-peptide quartile. However, the magnitude of HbA1c reduction was always greater in individuals
using an insulin pump compared with MDI therapy.
Vigersky et al. showed similar improvements in HbA1c,
total daily insulin dose, and treatment satisfaction among
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T2D patients ‡65 years using insulin pump therapy compared
with MDI irrespective of baseline C-peptide level.73
In a study of 331 T2D adults who were randomized to
insulin pump or MDI therapy, participants were categorized
into two groups according to baseline C-peptide level: Group
A (£183 pmol/L) and Group B (>183 pmol/L). At 6 months,
the MDI group crossed over to insulin pump therapy.
Between- and within-group comparisons were assessed at 6
and 12 months in the entire cohort and separately for those
patients ‡65 years of age. Significant HbA1c reductions were
observed at both 6 and 12 months among insulin pump users
in both C-peptide groups along with reductions in total daily
insulin dosages and improvements in treatment satisfaction. Similar findings were reported in the subgroup of older
participants.
The evidence clearly does not support the continued use
by Medicare of either the C-peptide or beta cell antibody assessment. Their use precludes many beneficiaries from adopting
this important technology. Worse, many individuals who
have been users of insulin pump therapy for years are denied
coverage for this therapy when failing to meet the C-peptide or
beta cell antibody standards when aging into Medicare, significantly disrupting their ability to successfully manage diabetes.
No evidence to support requirement for history
of MDI therapy

Given that the majority of individuals with T1D are currently treated with either MDI or insulin pump therapy, this
requirement specifically targets those with T2D. In our review of the T2D studies that showed glycemic benefits with
insulin pump use, we found two early studies that demonstrated improved outcomes in individuals with T2D who
were treated insulin pump therapy after earlier treatment with
less-intensive insulin therapy or oral medications.36,38 Although recent studies, such as the OpT2mise trial,34,35 listed
prior MDI therapy in their inclusion criteria, this requirement
was for study purposes only.
Although we agree that everyone who initiates insulin
pump therapy should be well-trained in intensive insulin
therapy, requiring use of MDI for 6 months (an arbitrary
timeframe, at best) negatively impacts beneficiaries who
develop the requisite skills in a shorter period of time. Again,
there is no scientific basis for the current requirement.
No evidence to support requirement for frequent BGM

Unlike recent CGM studies that definitively showed no association between earlier BGM frequency and glycemic outcomes,75–80 we were only able to identify one insulin pump
study without CGM use that even reported BGM frequency
(mean 2.5 times/day) as a baseline characteristic.34 We then
reviewed the clinical trials listed as references in the Decision
Memo for Insulin Pump: C-Peptide Levels as a Criterion for
Use (CAG-00092R).55 None of the studies cited in the Memo
listed frequency of BGM in their inclusion criteria.81–84
Even earlier studies, including the Diabetes Control and
Complications Trial85 and Lecavalier et al.,86 indicated that
frequent BGM was not a requirement for inclusion. Therefore, it must be assumed that the current requirement for ‡4
times daily blood glucose testing is not supported in the literature and it is unclear why CMS chose to include unsupported criteria in its coverage policy.
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The requirement also fails to consider the potential disruption of therapy for individuals who are newly enrolled in
Medicare. According to the criteria, well-controlled individuals who are currently using an insulin pump but transition
to Medicare find that only three strips per day are covered,
regardless of therapy. Those who do not fulfill the testing requirement before enrollment will lose use of their pump
until they satisfy the requirement. This disruption in care will
likely result in deterioration of glycemic control. As reported
in a study that assessed the impact of the CMS Competitive
Bidding program, the subsequent disruption of beneficiary
access to their BGM supplies resulted in a significant proportion of beneficiaries who reduced or discontinued BGM
use, leading to increased mortality, hospitalizations, and associated costs.87
In addition, Medicare’s standard coverage for test strips
provides coverage of only three test strips per day even for
patients needing intensified insulin therapy. To obtain Medicare coverage for four or more test strips per day, beneficiaries, health care providers, and suppliers must provide
extensive documentation that demonstrates the medical necessity for additional strips. The documentation requirements
are sufficiently complex that they discourage many suppliers
from providing more than three test strips per day. Thus, to
obtain four or more test strips per day, beneficiaries either pay
out-of-pocket for the additional test strips or convince their
health care provider to take additional time to document the
medical necessity for more frequent testing and negotiate
with suppliers to obtain the additional coverage.
Requiring poor glycemic control punishes
motivated beneficiaries

Limiting insulin pump coverage only to beneficiaries with
HbA1c >7%, or some other significant dysglycemia event,
not only marginalizes those who have been successful in following their self-management regimen but completely ignores current clinical guidelines for individualizing glycemic
targets based on each patient’s age and health status. In addition, because Medicare requires that beneficiaries have documented problematic glycemia (e.g., recurring hypoglycemia
and excessive glycemic variability), beneficiaries who have
achieved optimal glycemic control with insulin pump therapy
before enrolling in Medicare are denied use of the tool that
has enabled them to succeed with their self-management.
Use of CGM, with or without an insulin pump, has abrogated much of the problematic hyper- and hypoglycemia in
both MDI and insulin pump users, and this is further improved by the use of insulin pumps with automated insulin
delivery. The risks of these life-threatening events return
immediately after loss of either of these updated devices. The
use of antiquated requirements for life-saving therapies puts
patients and health care providers in a bind when patients
transition to Medicare from private insurance.
Quarterly in-person clinical visits
are medically unnecessary

The current requirement for quarterly in-person clinic visits is not based on evidence and directly contravenes the
current clinical emphasis on individualizing care.88,89 Moreover, this requirement has a direct impact on beneficiary
health behaviors and clinical outcomes. Results from an
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assessment of the T1D Exchange registry showed no change
in HbA1c levels across different frequency of visits in a
population of >600 patients ‡65 years of age.90 The requirement also imposes significant and unnecessary burden on
Medicare beneficiaries and caregivers related to the visits
themselves and to travel and time away from work. In addition, because Medicare will only cover an HbA1c test every
95 days, the discrepancy in visits and laboratory testing adds
additional work for patients and health care providers. These
inconsistencies in Medicare requirements (testing 4 · per
day but only covering three strips per day; visit requirements
every 90 days but HbA1c testing every 95 days) causes both
patients and health care providers nonproductive time and
effort.
In addition, this requirement ignores the utility of telemedicine visits. As reported in a recent systematic review
of 19 randomized controlled trials, use of telemedicine was
more effective in improving glycemic control and other
diabetes-related outcomes than usual care.91
The utility of telemedicine visits has also been clearly
demonstrated in addressing the challenges created by the
COVID-19 pandemic.92
Documentation requirements are burdensome

Changes in documentation requirements are also needed.
For example, access to insulin pump therapy is further hindered by the onerous documentation that health care providers are required to submit to obtain coverage for their
patients. In a 2017 survey conducted by the American Medical Association (AMA), 92% of the 1000 clinicians surveyed
reported that the documentation required to obtain authorization for medications and medical devices both delays patient treatment and negatively affects clinical outcomes.93
The current documentation requirements also have direct
impact on health behaviors, treatment satisfaction, and medication adherence. As reported by Argento et al. in a 2019
survey of 241 Medicare patients with T1D, 56% reported
difficulties in getting their supplies.94 The most common
complaints reported by respondents were delays in releasing
supplies (30%), difficulty in getting paperwork completed by
clinicians (24%), and problems scheduling quarterly visits
(18%). As a result, 39% of respondents reported changing
their pump-related behaviors such as delays in changing infusion sets (66%) and reusing supplies (34%).
These respondents reported significant adverse outcomes,
including more erratic glucose levels (48%), more frequent
hyperglycemia (17%), increased anxiety or frustration (44%),
pain or irritation at infusion set insertion sites (34%), more
scarring of sites (28%), and requiring emergency supply
shipments (19%) or getting emergency supplies from a local
source (15%). When asked to rate their overall experience with
Medicare, 28% rated Medicare coverage to be somewhat
worse and 31% much worse than earlier insurance. Additional
research is needed to fully elucidate the extent to which these
issues are impacting patient health and clinician efficiency.
Medication Adherence Impacts Clinical Outcomes
and Health Care Costs

Suboptimal adherence to diabetes medication regimens
remains a significant health concern for providers and payers.
As demonstrated in recent studies, medication nonadherence
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leads to poor outcomes,95,96 which can increase health care
service utilization and overall health care costs.97–99 Cutler
et al. estimated that the total cost attributable to nonadherence
in diabetes in the United States was >$5 billion, with an
average per-patient cost ranging from $2741 to $9819.100
A 2012 study by Egede et al. found that individuals who are
nonadherent to their diabetes medication regimens can have
annual inpatient costs 41% higher compared with those who
are adherent.99
Conversely, optimal medication adherence is associated
with improved glycemic control and decreased health care
resource utilization.101,102 In a 2016 study of 1000 T1D
adults (‡65 years), Boye et al. reported a significant association between higher adherence and overall decreased
costs, specifically those associated with acute diabetesrelated events, and that each 1% increase in adherence was
associated with an all-cause cost savings of $65,464 over
3 years.102
Ensuring that individuals with T2D are satisfied with their
treatment regimen is critical to improving adherence to diabetes medications, particularly in older T2D adults.103,104 In
a 2018 study that included 135 T2D adults (age 60 years),
treatment satisfaction was associated with an increase in
adherence to diabetes medications (b = 0.34, P = 0.02).104 In
an earlier study that assessed the effect of patient-selected
intensive insulin therapy on quality of life in individuals with
insulin-treated diabetes, Chantelau et al. reported higher
treatment satisfaction among those who were able to choose
their intensive insulin regimen (MDI or insulin pump).105 Of
interest, insulin pump treatment conferred greater protection
against hypoglycemia.
Studies have shown that low treatment satisfaction is associated with poor medication adherence.106,107 For individuals with insulin-treated diabetes, nonadherence to insulin
treatment is often because of the pain and fear associated with
injections.108–110 As reported by Rubin et al., the prevalence
of fear of injections in individuals with insulin-treated diabetes ranges from 10% to 26%.110
Because CMS considers diabetes medication adherence to
be a critical component of its medication-related quality
measures, as evidenced in its Part C and D Star Ratings (D10Medication Adherence for Diabetes Medications),111 it only
makes sense that individuals treated with intensive insulin
therapy have the option to choose the insulin delivery method
that meets their individual needs and preferences. Providing
individuals with options for treatment is an essential component of person-centered care.
One remedy for mitigating the issues and obstacles discussed here would be to simplify the eligibility criteria, requiring that only one of two conditions be met (Table 2). The
precedence for reliance on clinical judgment was set by
CMS in its waiver document issued during the COVID-19

Table 2. Proposed Eligibility Criteria
for Insulin Pump Coverage
1
2

Patients already treated with insulin pump therapy
before Medicare enrollment
OR
Patients with any type of diabetes who require
intensive insulin therapy based on the clinical
judgment of a licensed health care provider

pandemic regarding medical necessity for CGM coverage.112
All current criteria, including testing for C-peptide and beta
cell antibodies, history of glucose monitoring, frequency of
insulin adjustments based on glucose data, prior injection
therapy, and in-person clinic visits should be eliminated.
For documentation purposes, this would only require the
health care provider to check a box next to a statement that
reads: ‘‘The prescribing healthcare provider certifies that the
beneficiary is willing and able to consistently test blood
glucose using BGM or CGM prior to initiating pump therapy.’’ This certification would only be required at the time
when insulin pump therapy is initiated. It would not be needed for ongoing provision of insulin pump supplies or in
cases when a beneficiary was already treated with insulin
pump therapy before Medicare enrollment.
The proposed criteria would significantly reduce the administrative burden of obtaining coverage and eliminate
current requirements that are unduly restrictive and medically unfounded. In addition, the frequency of visits, either
in-person or using telemedicine visits should be reduced from
every 3 months to every 6 months, which aligns with the
frequency used by most health care providers with their CGM
patients. Finally, coverage for test strips should be increased
to five strips per day for MDI users and one strip per day for
those using CGM.
Conclusions

Given the importance of health behaviors and medication
adherence in daily diabetes self-management, it is incumbent
upon health care providers and payers to identify and remove
barriers that impede access to proven tools and technologies
that enable individuals with diabetes to achieve and maintain optimal glycemic control. As underscored in this article,
many of the current Medicare coverage criteria create significant barriers to beneficiaries who could benefit from insulin
pump therapy. Significant changes in these criteria are needed.
First, the requirement for laboratory assessments of
C-peptide and beta cell autoantibody levels should be eliminated. Well-designed studies that have shown no correlation
between success of insulin pump use and C-peptide/beta cell
autoantibody levels further support this position.35,56,72,73
Second, although frequent glucose testing (BGM or CGM)
is necessary for initiating and continuing use of insulin pump
therapy, an individual’s history of testing frequency before insulin pump initiation should not be a requirement for
coverage eligibility. Allowing beneficiaries to choose their
insulin-delivery method, in collaboration with their health
care provider, is critical to supporting treatment satisfaction,
a major driver of treatment adherence and subsequent outcomes.103–110 The added safety of insulin pumps with predictive low glucose suspend or automated insulin delivery
used in conjunction with CGM should be a strong consideration for insulin pump use by Medicare beneficiaries. Patient
choice matters.
Third, the quarterly clinic visit requirement has no scientific basis and should be eliminated. Instead, it should be up to
the health care provider’s clinical judgment to determine
when and how often the beneficiary should be seen. Moreover, patients who are unable to regularly attend their quarterly visits face delays in receiving their supplies on time. The
third-party suppliers will not release supplies if there is no
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chart note and HbA1c every 3 months, which causes further
burden to the patient, their health care provider, and the clinic
office that needs to provide these notes. Eliminating this
requirement would be entirely consistent with the newly
announced CMS proposal to lift unnecessary regulations and
ease burden on patients and providers.113
Changes in documentation requirements are also needed.
Access to insulin pump therapy is hindered by the onerous
documentation that health care providers are required to submit
to obtain coverage for their patients.93 The current documentation requirements also have direct impact on health behaviors, treatment satisfaction, and treatment adherence.94
According to the most recent CMS data, *67% of the
insulin-treated Medicare beneficiaries who are currently
treated with or will eventually transition to intensive insulin
therapy are denied access to insulin pump therapy because of
eligibility criteria that are medically unfounded.87 From our
perspective, insulin pump therapy should be made available
to all beneficiaries who would benefit from this technology,
are motivated to achieve optimal glycemic control, and have
the ability to safely and effectively use their insulin pump for
daily diabetes self-management.
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27. Šoupal J, Petruzelková L, Grunberger G, et al.: Glycemic
outcomes in adults with T1D are impacted more by continuous glucose monitoring than by insulin delivery
method: 3 years of follow-up from the COMISAIR study.
Diabetes Care 2020; 43:37–43.
28. Brown SA, Kovatchev BP, Raghinaru D, et al.; iDCL
Trial Research Group. Six-month randomized, multicenter
trial of closed-loop control in type 1 diabetes. N Engl J
Med 2019;381:1707–1717.

ALEPPO ET AL.

29. Bergenstal RM, Klonoff DC, Garg SK, et al.: Thresholdbased insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013;18;369:224–232.
30. Feig DS, Corcoy R, Donovan LE, et al.: Pumps or
multiple daily injections in pregnancy involving type 1
diabetes: a prespecified analysis of the CONCEPTT randomized trial. Diabetes Care 2018;41:2471–2479.
31. Feig DS, Donovan LE, Corcoy R, et al.: Continuous
glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet 2017;390:2347–2359.
32. Battelino T, Conget I, Olsen B, et al.: The use and efficacy of continuous glucose monitoring in type 1 diabetes
treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012;55:3155–3162.
33. Singh P, Pandey D, Trivedi N: Insulin pump in difficult
to control type 2 diabetes: a single center, five years’
experience. Cureus 2018;10:e3240.
34. Aronson R, Reznik Y, Conget I, et al.: Sustained efficacy of
insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise
randomized trial. Diabetes Obes Metab 2016;18:500–507.
35. Reznik Y, Cohen O, Aronson R, et al.: Insulin pump
treatment compared with multiple daily injections for
treatment of type 2 diabetes (OpT2mise): a randomised
open-label controlled trial. Lancet 2014;384:1265–1272.
36. Edelman SV, Bode BW, Bailey TS, et al.: Insulin pump
therapy in patients with type 2 diabetes safely improved
glycemic control using a simple insulin dosing regimen.
Diabetes Technol Ther 2010;12:627–633.
37. Layne JE, Parkin CG, Zisser H: Efficacy of a tubeless
patch pump in patients with type 2 diabetes previously
treated with multiple daily injections. J Diabetes Sci
Technol 2017;11:178–179.
38. Berthe E, Lireux B, Coffin C, et al.: Effectiveness of intensive insulin therapy by multiple daily injections and
continuous subcutaneous infusion: a comparison study in
type 2 diabetes with conventional insulin regimen failure.
Horm Metab Res 2007;39:224–229.
39. Wainstein J, Metzger M, Boaz M, et al.: Insulin pump
therapy vs. multiple daily injections in obese Type 2 diabetic patients. Diabet Med 2005;22:1037–1046.
40. Kesavadev J, Balakrishnan S, Ahammed S, Jothydev S:
Reduction of glycosylated haemoglobin following 6 months
of continuous subcutaneous insulin infusion in an Indian
population with T2D. Diabetes Technol Ther 2009;11:
517–521.
41. Conget I, Castaneda J, Petrovski G, et al.: The impact of
insulin pump therapy on glycemic profiles in patients with
type 2 diabetes: data from the OpT2mise study. Diabetes
Technol Ther 2016;18:22–28.
42. Cohen O, Korner A, Chlup R, et al.: Improved glycemic
control through continuous glucose sensor-augmented
insulin pump therapy: prospective results from a community and academic practice patient registry. J Diabetes
Sci Technol 2009;3:804–811.
43. Chlup R, Runzis S, Castaneda J, et al.: Complex assessment of metabolic effectiveness of insulin pump therapy
in patients with type 2 diabetes beyond HbA1c reduction.
Diabetes Technol Ther 2018;20:153–159.
44. Carlson AL, Huyett LM, Jantz J, et al.: Improved glycemic control in 3,592 adults with type 2 diabetes mellitus
initiating a tubeless insulin management system. Diabetes
Res Clin Pract 2021;174:108735.

CMS COVERAGE FOR CSII

45. Blevins T, Lane W, Rodbard D, et al.: Glucose variability
and time in range in type 2 diabetes treated with U-500r
by pump or injection: CGM findings from the VIVID
Study. Diabetes Technol Ther 2021;23:51–58.
46. Yeoh E, Beato-Vibora P, Rogers H, et al.: Efficacy of
insulin pump therapy in elderly patients. Diabetes Technol
Ther 2015;17:364–365.
47. Qu Y, Jacober SJ, Zhang Q, et al.: Rate of hypoglycemia
in insulin-treated patients with type 2 diabetes can be
predicted from glycemic variability data. Diabetes Technol Ther 2012;14:1008–1012.
48. Zhao MJY, Prentice JC, Mohr DC, Conlin PR: Association between hemoglobin A1c variability and hypoglycemiarelated hospitalizations in veterans with diabetes mellitus.
BMJ Open Diabetes Res Care 2021;9:e001797.
49. Forlenza GP, Li Z, Buckingham BA, et al.: Predictive
low-glucose suspend reduces hypoglycemia in adults,
adolescents, and children with type 1 diabetes in an athome randomized crossover study: results of the PROLOG trial. Diabetes Care 2018;41:2155–2161.
50. Breton MDS, Kovatchev BP: One year real-world use of
the Control-IQ advanced hybrid closed-loop technology.
Diabetes Technol Ther 2021. [Epub ahead of print]; DOI:
10.1089/dia.2021.0097.
51. Carlson AL, Bode BW, Brazg, et al.: 97-LB: Safety and
glycemic outcomes of the MiniMed advanced hybrid
closed-loop (AHCL) system in subjects with T1D. Diabetes 2020;69 (Suppl 1) 97-LB; DOI: 10.2337/db20-97LB.
52. Forlenza GP, Buckingham BA, Brown SA, et al.: First
Outpatient Evaluation of a Tubeless Automated Insulin
Delivery System with Customizable Glucose Targets in
Children and Adults with Type 1 Diabetes. Diabetes
Technol Ther 2021;23(6):410–424. http://doi.org/10.1089/
dia.2020.0546
53. LoopDocs. https://loopkit.github.io/loopdocs/system (accessed April 30, 2021).
54. Centers for Medicare & Medicaid Services: CMS.gov.
National Coverage Determination (NCD) for Infusion
PUMPs (280.14). https://www.cms.gov/medicare-cover
age-database/details/ncd-details.aspx?NCDId=223&ncdver=
2&NCAId=40&NcaName=Insulin+Infusion+Pump&Cov
erageSelection=National&KeyWord=insulin+pump&Key
WordLookUp=Title&KeyWordSearchType=And&bc=gAA
AABAACAAAAA%3D%3D& (accessed April 10, 2021).
55. Centers for Medicare & Medicaid Services: CMS.gov.
Decision Memo for Insulin Pump: C-Peptide Levels as a
Criterion for Use (CAG-00092R). https://www.cms.gov/
medicare-coverage-database/details/nca-decision-memo
.aspx?NCAId=109& (accessed April 10, 2021).
56. Gill M, Chhabra H, Shah M, et al.: C-peptide and beta-cell
autoantibody testing prior to initiating continuous subcutaneous insulin infusion pump therapy did not improve
utilization or medical costs among older adults with diabetes mellitus. Endocr Pract 2018;24:634–645.
57. Vigersky RA, Huang S, Cordero TL, et al: Improved
HbA1c, total daily insulin dose, and treatment satisfaction
with insulin pump therapy compared to multiple daily
insulin injections in patients with type 2 diabetes irrespective of baseline c-peptide levels. Endocr Pract 2018;
24:446–452.
58. Lajara R, Fetchick DA, Morris TL, Nikkel C: Use of
V-Go insulin delivery device in patients with suboptimally controlled diabetes mellitus: a retrospective

9

59.
60.

61.

62.

63.

64.

65.
66.
67.
68.
69.

70.

71.

72.

73.

74.

analysis from a large specialized diabetes system. Diabetes Ther 2015;6:531–545.
Leighton E, Sainsbury CA, Jones GC: A practical review
of C-peptide testing in diabetes. Diabetes Ther 2017;8:
475–487.
Keenan HA, Sun JK, Levine J, et al.: Residual insulin
production and pancreatic ß-cell turnover after 50 years of
diabetes: Joslin Medalist Study. Diabetes. 2010;59:2846–
2853.
Wang L, Lovejoy NF, Faustman DL: Persistence of prolonged c-peptide production in type 1 diabetes as measured with an ultrasensitive c-peptide assay. Diabetes Care
2012;35:465–470.
Greenbaum CJ, Beam CA, Boulware D, et al.: Fall in
c-peptide during first 2 years from diagnosis: evidence of
at least two distinct phases from composite type 1 diabetes
TrialNet Data. Diabetes 2012;61:2066–2073.
Lachin JM, McGee P, Palmer JP for the DCCT/EDIC
Research Group: Impact of c-peptide preservation on
metabolic and clinical outcomes in the Diabetes Control
and Complications Trial. Diabetes. 2014;63:739–748.
Khan HA, Sobki SH, Ekhzaimy A, et al.: Biomarker potential of C-peptide for screening of insulin resistance in
diabetic and non-diabetic individuals. Saudi J Biol Sci
2018;25:1729–1732.
Min J-Y, Min K-B: Serum C-peptide levels and risk of
death among adults without diabetes mellitus. CMAJ
2013;185:E402–E408.
de León AC, Garcı́a JGO, Rodrı́guez IM, et al.: C-peptide
as a risk factor of coronary artery disease in the general
population. Diab Vasc Dis Res 2015;12:199–207.
Patel N, Taveira TH, Choudhary G, et al.. Fasting serum
C-peptide levels predict cardiovascular and overall death
in nondiabetic adults. J Am Heart Assoc 2012;1:e003152.
Wondmkun YT: Obesity, insulin resistance, and type 2
diabetes: associations and therapeutic implications. Diabetes Metab Syndr Obes 2020; 13: 3611–3616
Christensen MB, Gæde P, Hommel E, et al.: Glycaemic
variability and hypoglycaemia are associated with
C-peptide levels in insulin-treated type 2 diabetes. Diabetes Metab 2020;46:61–65.
Gumus P, Gomez R, Vargas A, Chalew S: The relationship of insulin secretion and gad65 antibody levels at diagnosis on glycemic control in type 2 diabetes. J Pediatr
Endocrinol Metab 2010;23:1025–1029.
Davies MJ, D’Alessio DA, Fradkin J, et al.: Management
of hyperglycaemia in type 2 diabetes, 2018. A consensus
report by the American Diabetes Association (ADA) and
the European Association for the Study of Diabetes
(EASD). Diabetes Care 2018;61:2461–2498.
Reznik Y, Huang S: Reductions in a1c with pump therapy
in type 2 diabetes are independent of c-peptide and antiglutamic acid decarboxylase antibody concentrations.
Diabetes Technol Ther 2014;16:816–818.
Vigersky RA, Huang S, Cordero TL, et al.: Improved
HbA1c, total daily insulin dose, and treatment satisfaction
with insulin pump therapy compared to multiple daily
insulin injections in patients with type 2 diabetes irrespective of baseline C-peptide levels. Endocr Pract 2018;
24:446–452.
Guzmán G, Martı́nez V, Yara JD, et al.: Glycemic control
and hypoglycemia in patients treated with insulin pump
therapy: an observational study. J Diabetes Res 2020;
2020:1581726.

10

75. Beck RW, Riddlesworth T, Ruedy K, et al.: Effect of continuous glucose monitoring on glycemic control in adults with
type 1 diabetes using insulin injections: The DIAMOND
randomized clinical trial. JAMA 2017; 317:371–378.
76. Beck RW, Riddlesworth TD, Ruedy K, et al.: Continuous
glucose monitoring versus usual care in patients with
type 2 diabetes receiving multiple daily insulin injections:
a randomized trial. Ann Intern Med 2017;167:365–374.
77. Ruedy KJ, Parkin CG, Riddlesworth TD, et al.: Continuous glucose monitoring in older adults with type 1 and
type 2 diabetes using multiple daily injections of insulin:
results from the DIAMOND trial. J Diabetes Sci Technol
2017;11:1138–1146.
78. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, et al.:
Novel glucose-sensing technology and hypoglycemia in
type 1 diabetes: a multicentre, non-masked, randomised
controlled trial. Lancet 2016;388:2254–2263.
79. Haak T, Hanaire H, Ajjan R, et al.: Use of flash glucose
sensing technology for 12 months as a replacement for
blood glucose monitoring in insulin-treated type 2 diabetes. Diabetes Ther 2017;8:573–586.
80. Haak T, Hanaire H, Ajjan R, et al.: Flash glucose-sensing
technology as a replacement for blood glucose monitoring
for the management of insulin-treated type 2 diabetes: a
multicenter, open-label randomized controlled trial. Diabetes Ther 2017;8:55–73.
81. Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, et al.:
The study group for the development of pump therapy in
diabetes: comparison of continuous subcutaneous insulin
infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified
treatment. Diabetes Care 2000;23:1232–1235.
82. Jennings A, Lewis K, Murdoch S, et al.: Randomized trial
comparing continuous subcutaneous insulin infusion and
conventional insulin therapy in type II diabetic patients
poorly controlled with sulfonylureas. Diabetes Care 1991;
14:738–744.
83. Linn T, Mann M, Mann M, et al.: Randomized prospective study for the effect of therapy on residual beta cell
function in type I diabetes mellitus. BMC Endocrine
Disorders 2003;3:5.
84. Raskin P, Bode BW, Marks JB, et al.: Continuous subcutaneous insulin infusion and multiple daily injection therapy are
equally effective in type 2 diabetes: a randomized, parallelgroup, 24-week study. Diabetes Care 2003;26:2598–2603.
85. Protocol for Diabetes Control and Complications Trial
(DCCT): Diabetes Care Nov 1982;5:XXIX-XXX; DOI:
10.2337/diacare.5.6.XXIX.
86. Lecavalier L, Havrankova J, Hamet P, Chiasson J: Effects
of continuous subcutaneous insulin infusion versus multiple injections on insulin receptors in insulin-dependent
diabetics. Diabetes Care 1987;10:300–305.
87. Puckrein GA, Nunlee-Bland G, Zangeneh F, et al.: Impact of
CMS competitive bidding program on medicare beneficiary
safety and access to diabetes testing supplies: a retrospective,
longitudinal analysis. Diabetes Care 2016;39:563–571.
88. American Diabetes Association: 7. Diabetes technology.
Standards of medical care-2019. Diabetes Care 2019: 42
(Suppl 1): S71–S80.
89. Grunberger G, Abelseth J, Bailey T, et al.: Consensus
statement by the American Association of Clinical
Endocrinologists/American College of Endocrinology Insulin Pump management task force. Endocr Pract 2014;
20:463–489.

ALEPPO ET AL.

90. Argento N, Peters A: Impact of Center for Medicare Services (CMS) insulin pump policies on patients with T1D.
Poster presented at: American Diabetes Association 77th
Scientific Session; June 2017; San Diego, CA, 1036-P.
91. Wu C, Wu Z, Yang L, et al.: Evaluation of the clinical
outcomes of telehealth for managing diabetes. Medicine
(Baltimore). 2018;97:e12962.
92. Monaghesh E, Hajizadeh A: The role of telehealth during
COVID-19 outbreak: a systematic review based on current
evidenceBMC Public Health 2020;20:1193.
93. American Medical Association (AMA): 2017 AMA Prior
Authorization Physician Survey. https://www.ama-assn
.org/sites/ama-assn.org/files/corp/media-browser/public/arc/
prior-auth-2017.pdf (accessed March 1, 2021).
94. Argento NB, Liu J, Hughes AS, McAuliffe-Fogarty AH:
Impact of medicare continuous subcutaneous insulin infusion policies in patients with type 1 diabetes. J Diabetes
Sci Technol. 2020;14:257–261.
95. Polonsky WH, Henry RR: Poor medication adherence in
type 2 diabetes: recognizing the scope of the problem and
its key contributors. Patient Prefer Adherence 2016;10:
1299–1307.
96. Alqarni AM, Alrahbeni T, Al Qarni A, Al Qarni HM:
Adherence to diabetes medication among diabetic patients
in the Bisha governorate of Saudi Arabia—a crosssectional survey. Patient Prefer Adherence 2019;13:
63–71.
97. Iuga AO, McGuire MJ: Adherence and health care costs.
Risk Manag Healthc Policy 2014;7:35–44.
98. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS:
Impact of medication adherence on hospitalization risk
and healthcare cost. Med Care 2005;43:521–530.
99. Egede LE, Gebregziabher M, Dismuke CE, et al.: Medication nonadherence in diabetes: Longitudinal effects on
costs and potential cost savings from improvement. Diabetes Care 2012;35:2533–2539.
100. Cutler RC, Fernandez-Llimos F, Frommer M, et al.:
Economic impact of medication non- adherence by disease groups: a systematic review. BMJ Open 2018;8:
e016982.
101. Asche C, LaFleur J, Conner C: A review of diabetes
treatment adherence and the association with clinical and
economic outcomes. Clin Ther 2011;33:74–109.
102. Boye KS, Curtis SE, Lage MJ, Garcia-Perez LE: Associations between adherence and outcomes among older,
type 2 diabetes patients: evidence from a Medicare Supplemental database. Patient Prefer Adherenc 2016;10:
1573–1581.
103. Hsu C, Lemon JM, Wong ES, et al.: Factors affecting
medication adherence: Patient perspective from five veterans affairs facilities. BMC Health Serv Res 2014;14:
533–541.
104. Emechebe N, Agu N, Malm M, Zgibor JC: Examining the
association between treatment satisfaction and medication
adherence among patients with poorly controlled type 2
diabetes. Diabetes 2018;67 (Supplement 1):724-P.
105. Chantelau E, Schiffers T, Schütze J, Hansen B: Effect of
patient-selected intensive insulin therapy on quality of
life. Patient Educ Couns 1997;30:167–173.
106. Khdour MR, Awadallah HB, Al-Hamed DaH: Treatment
satisfaction and quality of life among type 2 diabetes
patients: a cross-sectional study in West Bank, Palestine.
J Diabetes Res 2020;1–8. [Epub ahead of print]; DOI:
10.1155/2020/1834534.

CMS COVERAGE FOR CSII

107. Khunti N, Khunti N, Khunti K: Adherence to type 2 diabetes management. Br J Diabetes 2019;19:99–104.
108. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger
PM. Insulin adherence behaviors and barriers in the
multinational global attitudes of subjects and physicians in
insulin therapy study. Diabet Med 2012;29:682–689
109. Wibisono AH, Lestari An, Sorensen L, Hill P: Fear of
injections among people with type 2 diabetes: overview of
the problem. J Diabetes Nurs 2017;21: 91–95.
110. Rubin RR, Peyrot M, Kruger DF, Travis LB: Barriers to
insulin injection therapy: patient and health care provider
perspectives. Diabetes Educ 2009;35:1014–1022.
111. Centers for Medicare & Medicaid Services: CMS.gov.
Fact Sheet - 2021 Part C and D Star Ratings. https://www
.cms.gov/files/document/2021starratingsfactsheet-10-132020.pdf (accessed April 5, 2021).
112. Centers for Medicare & Medicaid Services: COVID-19
emergency declaration blanket waivers for health care

11

providers. https://www.cms.gov/files/document/summarycovid-19-emergency-declaration-waivers.pdf
(accessed
April 28, 2021).
113. Centers for Medicare & Medicaid Services (CMS):
CMS.gov. CMS Proposes to Lift Unnecessary Regulations
and Ease Burden on Providers. https://www.cms.gov/news
room/press-releases/cms-proposes-lift-unnecessary-regula
tions-and-ease-burden-providers (accessed April 5, 2021).

Address correspondence to:
Christopher G. Parkin, MS
Clinical Research
CGParkin Communications, Inc.
2352 Martinique Avenue
Henderson, NV 89044
USA
E-mail: chris@cgparkin.org

